Click here to view online. Add this email to your safelist.
Year-to-date and Q3 2022 results
10 November 2022
Pascal Soriot, Chief Executive Officer, commenting on the results said:
“AstraZeneca continues to see the benefit of our sustained investment in R&D, with 19 major regulatory approvals since our last earnings call.”
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
